ABVC - ABVC Biopharma Stock Price, Fair Value and News

$0.540.00 (0.00%)

Delayed as of 22 Oct 2024, 09:31 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ABVC Price Action

Last 7 days

Last 30 days

-22.9%

Last 90 days

-31.6%

Trailing 12 Months

-40.7%

ABVC RSI Chart

ABVC Valuation

Market Cap

6.7M

Price/Earnings (Trailing)

-0.58

Price/Sales (Trailing)

141.37

EV/EBITDA

-0.69

Price/Free Cashflow

-2.02

ABVC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ABVC Fundamentals

ABVC Revenue

Revenue (TTM)

65.9K

Rev. Growth (Yr)

4.33%

Rev. Growth (Qtr)

40.48%

ABVC Earnings

Earnings (TTM)

-11.6M

Earnings Growth (Yr)

45.03%

Earnings Growth (Qtr)

67.64%

ABVC Profitability

Operating Margin

-156.88%

EBT Margin

-18039.64%

Return on Equity

-139.97%

Return on Assets

-79.33%

Free Cashflow Yield

-49.58%

ABVC Investor Care

Shares Dilution (1Y)

214.37%

Diluted EPS (TTM)

-1.67

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	96.8K	86.5K	76.2K	65.9K
2022	0	0	0	107.2K
2021	0	0	0	0
2020	568.3K	0	0	0
2019	470.0K	547.3K	624.5K	701.7K
2018	0	238.3K	315.6K	392.8K
2017	71.1K	161.1K	0	0
2016	0	0	0	73.4K
2015	3.0K	2.3K	3.4K	0
2013	26.9K	7.8K	7.8K	0
2012	0	0	24.9K	29.9K
2011	0	0	0	0
2010	0	0	434.1K	0

Get all data in R, Python etc through our Historical Stock Data APIs

About ABVC Biopharma

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.

WEBSITE	abvcpharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	19

ABVC Biopharma Frequently Asked Questions

What is the ticker symbol for ABVC Biopharma? What does ABVC stand for in stocks?

ABVC is the stock ticker symbol of ABVC Biopharma. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ABVC Biopharma (ABVC)?

As of Mon Oct 21 2024, market cap of ABVC Biopharma is 6.71 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABVC stock?

You can check ABVC's fair value in chart for subscribers.

Is ABVC Biopharma a good stock to buy?

The fair value guage provides a quick view whether ABVC is over valued or under valued. Whether ABVC Biopharma is cheap or expensive depends on the assumptions which impact ABVC Biopharma's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABVC.

What is ABVC Biopharma's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Oct 21 2024, ABVC's PE ratio (Price to Earnings) is -0.58 and Price to Sales (PS) ratio is 141.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABVC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ABVC Biopharma's stock?

In the past 10 years, ABVC Biopharma has provided -0.604 (multiply by 100 for percentage) rate of return.